The cardiac biomarkers market size is estimated to be USD 13,996.5 million in 2022 and is expected to witness a CAGR of 14.87% during the forecast period 2023-2033. Rising incidence of acute coronary syndrome, technological developments in cardiac biomarkers, increasing preference for point-of-care (POC) cardiac testing kits, and high precision in the detection of cardiac diseases, particularly myocardial infarction are factors contributing to the market growth. Additionally, rise in prevalence of cardiovascular diseases and growing use of cardiac biomarkers in SARS-CoV-2 patients to reduce the risk of heart disorders is expected to support the market growth. However, is expected to hinder the growth.

Rise in prevalence of cardiovascular diseases is expected to propel the market growth. According to the WHO, 17.9 million deaths globally from cardiovascular diseases per year by 2021, representing for 32% of all deaths. In the United States, cardiovascular diseases constitute the main cause of mortality and morbidity. Since they assist to understand better the pathophysiology of cardiovascular disorders, companies are currently concentrating on the identification of cardiac biomarkers. Roche Diagnostics’ Elecsys Troponin T-Gen 5 STAT, a cardiac biomarker, provides data in 9 minutes and supports in prompt decision-making.

Growing use of cardiac biomarkers in SARS-CoV-2 patients to reduce the risk of heart disorders is expected to fuel the market growth. For instance, according to NCBI in 2021, increased levels of cardiac injury biomarkers were identified in difficult COVID-19 patient cases, and the biomarkers were directly associated to diseases prognoses. As a result, the use of cardiac biomarkers made it possible to manage patients with advanced disease.

Segmentation

By Type

The market is categorized into myoglobin, troponin, CK-MB, BNP & NT-proBNP, and others. In 2022, the troponin segment accounted for the highest revenue share due to its high effectiveness, specificity, and accurate predictive detection of cardiac events. The global increase in myocardial infarction and stroke rates also contributes to the market’s expansion. The BNP and NT-proBNP segment is anticipated to have significant growth due to its application in the detection of stress and cardiac injury. In order to produce attractive revenues, new players are entering the market with the test. For instance, LumiraDx Limited announced in June 2022 that its CE Mark for the D-Dimer test and NT-proBNP test would diversify its range. By the end of 2022, it is anticipated that the latter would be available commercially, which might improve clinical decision-making easier.

By Application

The market is categorized into myocardial infarction, acute coronary syndrome, congestive heart failure, and others. In the global market, the acute coronary syndrome segment accounted for the largest revenue share in 2022 owing to fact that disease burden is increasing in low- and middle-income nations when compared to high-income countries. Rapid urbanisation and a rise in sedentary jobs are two factors contributing to the disease’s prevalence. Myocardial infarction is expected to have profitable expansion as a result of its rising incidence internationally. The significant focus that researchers are providing to myocardial infarction is predicted to lead to lucrative opportunities in the market. For instance, according to the Science Journal, research reported 27 new proteins in 2022 that can be used to individually to predict the risk of myocardial infarction.

By End User

The market is segmented into point-of-care testing and laboratory testing. In 2022, the laboratory testing segment accounted for the largest revenue share owing to benefits that laboratory testing provides, including its high sensitivity, specificity, scalability, and cost-effectiveness. The point of care (POC) testing market is expanding exponentially as a result of rising usage and adopting POC Troponin tests, that are extremely sensitive and easy to use. Additionally, in times of emergency, these tests are the first choice of medical professionals to diagnose patients more quickly. The rising global trend of the ageing population is the primary factor driving the demand for POC test kits for usage in nursing homes and at-home healthcare.

Regional Markets

In 2022, North America region accounted for the highest revenue in the cardiac biomarkers market and is expected to maintain its dominance during the forecast period. This is attributed to the advanced healthcare system and the widespread use of cardiac biomarkers as a diagnostic and prognostic tool for diseases. The demand for testing products is being driven by the growing elderly population’s need for biomarker testing to diagnose diseases such acute myocardial infarction. Another element supporting the expansion of this market is the presence of important companies such as Quidel Corporation and Danaher Corporation in the region. Asia Pacific is anticipated to grow significantly during the forecast period due to rising affordability of advanced cardiac tests, country development, and rising disposable income. Government funding for target disease and other research, and healthcare costs, have expanded due to the rising incidence of cardiovascular diseases (CVDs) in this region. Comparing India to other developing countries, it has a higher rate of CVDs. It is anticipated that the high disease burden in the region may increase demand for cardiac biomarker diagnostics, which will assist in the early diagnosis, evaluation, and treatment of CVDs.

Competitor Insights

Some of the key players operating in the cardiac biomarkers market are Randox Laboratories Ltd., Creative Diagnostics, Abbott, F. Hoffmann-La Roche Ltd., Quidel Corporation, Danaher Corporation, Biomérieux SA, Bio-Rad Laboratories, Inc., Siemens Healthineers, and Life Diagnostics.

To achieve a competitive edge, these businesses are implementing a variety of growth strategies. Strategic partnerships, alliances, and agreements with different businesses and research institutions are seen to be the main strategies used by companies in this sector.

• For instance, Roche announced a series of five new planned uses for two important cardiac biomarkers in April 2021 using the Elecsys technology, which has the NT-proBNP and highly sensitive cardiac troponin T. (cTnT-hs). This is anticipated to enhance risk diagnosis and detection while enabling the company to boost income from its current products.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including type, application, and end user from 2023 to 2033.

Report Scope:

Segmentation: Cardiac Biomarkers Market Report 2022 – 2033

Type (Revenue, USD Million), 2022 – 2033

• Myoglobin
• Troponin
• CK-MB
• BNP & NT-proBNP
• Others

Application (Revenue, USD Million), 2022 – 2033

• Myocardial Infarction
• Acute Coronary Syndrome
• Congestive Heart Failure
• Others

End user (Revenue, USD Million), 2022 – 2033

• Point-of-care Testing
• Laboratory Testing

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA